Caravan Biologix Partners with KOMO Biosciences to Advance Mini-CAR Cell Therapy Using KOMbine Platform

Caravan Biologix Received a Research License for the KOMbine™ Platform

Announcement

KOMO Biosciences, a known precision genome engineering offered a research license to Caravan Biologix, a commendable innovator in advancing mini-CAR technology, and a miniature T-cell that holds the natural immune power of the body. The KOMbine research license will allow caravan to assess and analyze KOMPO’s efficient insertion technology platform for a specific, timely research period. In the last year and a few months, since the establishment of KOMO Biosciences its establishment the company has managed to feature on the social platform for its valuable commitment to include manufacturing, agricultural, synthetic, and drug development in biotechnology through its gene insertion platform, along with the applications is a huge contribution to the healthcare market.

Among the competitive healthcare giants, the concentration of KOMO remains unshakable. With this, research license to the technology company, the approach and acceptance of the technology have uplifted and empowered many technology startups to discover new technologies for gene transfer or insertion. The integration of technologies into the healthcare sector has always been appreciative. The KOMbine platform will enhance KOMO’s progress and allow Caravan to demonstrate its potential in technology studies. Together, both companies will expand growth and development in the healthcare sector.

Agreement

The license agreement states that the caravan can access the KOMbine platform for developing the combined mini-CAR construction initiated to induce pluripotent stem cells (iPSCs). The compilation of technologies focuses on shortening the development timeframe, enhancing durability and potency, and reducing manufacturing costs of the caravan’s extensive range of mini-CAR candidates for solid tumors.

Views and Statements

CEO and Chief Science Officer of Caravan Biologix, Thomas Malcolm, said, “KOMO’s brilliant platform serves as a trustworthy and effective path to elevate, precisely, the insertion of multi-kilobase payloads in primary immune cells and iPSCs. This is what we need to develop our next generation’s mini-CAR products. We are excited to evaluate KOMbine with our existing platform, along with the motive to advance various of our solid tumor programs into IND-enabling studies.”

Founder CEO of KOMO Biosciences, Jennifer Manning, said, “Caravan’s visionary goal of liberalizing cell therapy lines up best with our mission to identify urgent patient needs by providing scalable and efficient genome engineering solutions in modalities and cell types. By combining caravan’s mini-CAR architecture and KOMbine, we will start working towards reproducing and fastening manufacturing processes and leveraging patient access to advanced therapies.”